Savara Inc. (SVRA) is a publicly traded Healthcare sector company. As of May 21, 2026, SVRA trades at $4.95 with a market cap of $1.01B and a P/E ratio of -9.48. SVRA moved +7.84% today. Year to date, SVRA is -12.41%; over the trailing twelve months it is +62.04%. Its 52-week range spans $1.89 to $7.01. Analyst consensus is strong buy with an average price target of $11.00. Rallies surfaces SVRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Savara’s Molbreevi Gains FDA Priority Review with Aug. 22 PDUFA Date: FDA accepted Savara’s BLA for Molbreevi in autoimmune PAP with priority review and an Aug. 22, 2026 PDUFA date. Phase III IMPALA showed DLCO, SGRQ, exercise capacity and surfactant burden improvements; Savara holds $264M cash and up to $150M of contingent funding.
| Metric | Value |
|---|---|
| Price | $4.95 |
| Market Cap | $1.01B |
| P/E Ratio | -9.48 |
| EPS | $-0.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.01 |
| 52-Week Low | $1.89 |
| Volume | 476 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-118.84M |
| Gross Margin | 0.00% |
6 analysts cover SVRA: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.00.